Key facts
- GAIA BioMedicine’s last known valuation is $88.4M (Jul 2025).
- It has raised $37.6M; the latest was Later Stage VC ($14.7M) in Jul 2025.
- Notable investors include Mitsubishi UFJ Capital, SBI Investment, JIC Venture Growth Investments, UntroD, Osaka University Venture Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for GAIA BioMedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for GAIA BioMedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GAIA BioMedicine
Operator of a biopharmaceutical company intended to deliver cancer immuno-cell therapy. The company offers antibody-anchoring peptide technology, tumor infiltration, and off-the-shelf cell formulations that help to eliminate solid tumors without genetic modification, enabling patients to fight intractable diseases using the power of genes and the immune system.
- Sector
- Healthcare
- HQ
- Fukuoka, Japan
- Founded
- 2015
- Website
- gaia-biomed.com/
- Ownership
- Privately Held (backing)
GAIA BioMedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GAIA BioMedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GAIA BioMedicine in its N-PORT filings yet. We sweep new filings monthly.